Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 320 shares at $259.58 ($83K) on 2022-05-02, disclosed to the SEC on 2022-05-04.
Scheduled sale ($83k) by EVP, Cell & Genetic Therapies under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $255.47 | 20 | $5K | 6.2% |
| 2 | $257.49 | 90 | $23K | 27.9% |
| 3 | $258.46 | 43 | $11K | 13.4% |
| 4 | $259.58 | 75 | $19K | 23.5% |
| 5 | $260.44 | 23 | $6K | 7.2% |
| 6 | $261.79 | 65 |
| $17K |
| 20.5% |
| 7 | $264.37 | 4 | $1K | 1.3% |
| Total | $259.16 avg | 320 | $83K | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |